LONDON, Jul 23, 2008 (Thomson Financial via COMTEX) - GSK | Quote | Chart | News | PowerRating -- Shares in GlaxoSmithKline Plc. were lower at midday after interim results failed to impress, with Hargreaves Lansdown saying the "results are likely to disappoint" investors.
At 1:29 a.m., GlaxoSmithKline shares were down 24-1/2 pence at 1,199-1/2, while the FTSE 100 index was ahead 60.9 points at 5,425.
ion. In conclusion, the results are likely to disappoint, with only the new management's strategy vision offering some consolation. On balance, market consensus opinion is neutral in tone."

LONDON (AFP) - British pharmaceutical giant GlaxoSmithKline said on Wednesday that net profits slipped during the second quarter owing to competition from generic drugmakers and poor sales of diabetes drug Avandia.
GSK's new chief executive Andrew Witty used his maiden results to unveil a major strategy overhaul aimed at diversifying the group's operations as it seeks higher growth and to reduce risk.
venues plunged by 46 percent to 194 million pounds in the reporting period.

LONDON - GlaxoSmithKline PLC, the world's second-largest drug maker, posted a three per cent drop in second-quarter profit on Wednesday, after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job cuts.
As rising generic sales continue to eat away at its profits, Glaxo also unveiled plans to grab a share of that market itself, announcing an alliance with South African company Aspen Pharmacare Holdings.
ll year at constant exchange rates.